Injectable and Oral Contraceptive Use and Cancers of the Breast, Cervix, Ovary, and Endometrium in Black South African Women: Case–Control Study

English version České info

Background:
Oral contraceptives are known to influence the risk of cancers of the female reproductive system. Evidence regarding the relationship between injectable contraceptives and these cancers is limited, especially in black South Africans, among whom injectable contraceptives are used more commonly than oral contraceptives.

Methods and Findings:
We analysed data from a South African hospital-based case–control study of black females aged 18–79 y, comparing self-reported contraceptive use in patients with breast (n = 1,664), cervical (n = 2,182), ovarian (n = 182), and endometrial (n = 182) cancer, with self-reported contraceptive use in 1,492 control patients diagnosed with cancers with no known relationship to hormonal contraceptive use. We adjusted for potential confounding factors, including age, calendar year of diagnosis, education, smoking, alcohol, parity/age at first birth, and number of sexual partners. Among controls, 26% had used injectable and 20% had used oral contraceptives. For current and more recent users versus never users of oral or injectable contraceptives, the odds ratios (ORs) for breast cancer were significantly increased in users of oral and/or injectable contraceptives (OR 1.66, 95% CI 1.28–2.16, p<0.001) and separately among those exclusively using oral (1.57, 1.03–2.40, p = 0.04) and exclusively using injectable (OR 1.83, 1.31–2.55, p<0.001) contraceptives; corresponding ORs for cervical cancer were 1.38 (1.08–1.77, p = 0.01), 1.01 (0.66–1.56, p = 0.96), and 1.58 (1.16–2.15, p = 0.004). There was no significant increase in breast or cervical cancer risk among women ceasing hormonal contraceptive use ≥10 y previously (p = 0.3 and p = 0.9, respectively). For durations of use ≥5 y versus never use, the ORs of ovarian cancer were 0.60 (0.36–0.99, p = 0.04) for oral and/or injectable contraceptive use and 0.07 (0.01–0.49, p = 0.008) for injectable use exclusively; corresponding ORs for endometrial cancer were 0.44 (0.22–0.86, p = 0.02) and 0.36 (0.11–1.26, p = 0.1).

Conclusions:
In this study, use of oral and of injectable hormonal contraceptives was associated with a transiently increased risk of breast and cervical cancer and, for long durations of use, with a reduced risk of ovarian and endometrial cancer. The observed effects of injectable and of oral contraceptives on cancer risk in this study did not appear to differ substantially.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Injectable and Oral Contraceptive Use and Cancers of the Breast, Cervix, Ovary, and Endometrium in Black South African Women: Case–Control Study. PLoS Med 9(3): e32767. doi:10.1371/journal.pmed.1001182
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001182

Souhrn

Zdroje

1. United Nations Department of Economic and Social Affairs Population Division 2009 World contraceptive use 2009. POP/DB/CP/Rev2009 New York United Nations

2. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat 2010 World population prospects: the 2010 revision. Available: http://esa.un.org/wpp/Excel-Data/population.htm. Accessed 6 January 2012

3. CoglianoVGrosseYBaanRStraifKSecretanB 2005 Carcinogencity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 6 552 553

4. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans 2007 Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. IARC Monogr Eval Carcinog Risks Hum 91 1 528 Lyon (France): International Agency for Research on Cancer

5. Collaborative Group on Epidemiological Studies of Ovarian Cancer 2008 Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet 371 303 314

6. International Agency for Research on Cancer 1999 Hormonal contraception and post-menopausal hormonal therapy Lyon (France) International Agency for Research on Cancer

7. Collaborative Group on Hormonal Factors in Breast Cancer 1996 Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347 1713 1727

8. StromBLBerlinJAWeberALNormanSABernsteinL 2004 Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception 69 353 360

9. SweeneyCGiulianoABaumgartnerKByersTHerrickJ 2007 Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women. Int J Cancer 121 2517 2523

10. ShapiroSRosenbergLHoffmanMTruterHCooperD 2000 Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 151 396 403

11. International Collaboration of Epidemiological Studies of Cervical Cancer 2007 Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data from 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies. Lancet 370 1609 1671

12. WHO Collaborative Study of Neoplasia and Steroid Hormones 1991 Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 49 186 190

13. LiangAPLevensonAGLaydePMSheltonJDHatcherRA 1983 Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections. JAMA 249 2909 2912

14. WHO Collaborative Study of Neoplasia and Steroid Hormones 1991 Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. Int J Cancer 49 191 195

15. BailieR 1997 A case control study of breast cancer risk and exposure to injectable progestogen contraceptives. S Afr Med J 87 302 305

16. SitasFCarraraHBeralVNewtonRReevesG 1999 Antibodies against human herpesvirus 8 in black South African patients with cancer. N Eng J Med 340 1863 1871

17. Pacella-NormanRUrbanMSitasFCarraraHSurR 2002 Risk factors for oesophageal, lung, oral and laryngeal cancers in black South Africans. Br J Cancer 86 1751 1756

18. SteinLUrbanMWeberMRuffPHaleM 2008 Effects of tobacco smoking on cancer and cardiovascular disease in urban black South Africans. Br J Cancer 98 1586 1592

19. LiuBQPetoRChenZ-MBorehamJWuY-P 1998 Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. BMJ 317 1411 1422

20. South Africa National Department of Health 2008 Standard treatment guidelines and essential drugs list for South Africa: primary care Pretoria National Department of Health

21. KeyTJVerkasaloPKBanksE 2001 The epidemiology of breast cancer. Lancet Oncol 2 133 140

22. Collaborative Group on Hormonal Factors in Breast Cancer 1996 Breast cancer and hormonal contraceptives: further results. Contraception 54 1S 106S

23. WernliKRayRMGaoDLDe RoosACheckowayH 2006 Menstrual and reproductive factors in relation to risk of endometrial cancer in Chinese women. Cancer Causes Control 17 949 955

24. LinetMSBrookmeyerR 1987 Use of cancer controls in case-control cancer studies. Am J Epidemiol 125 1 11

25. SteinLUrbanMO'ConnellDYuXBeralV 2008 The spectrum of human immunodeficiency virus-associated cancers in a South African black population: results from a case-control study, 1995–2004. Int J Cancer 122 2260 2265

26. BouvardVBaanRStraifKGrosseYSecretanB 2009 A review of human carcinogens—part B: biological agents. Lancet Oncol 10 321 322

27. DollRPetoRBorehamJSutherlandI 2004 Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 328 1519 1528

28. Statistics South Africa 2003 Census 2001: census in brief Pretoria Statistics South Africa Available: http://www.statssa.gov.za/census01/html/CInBrief/CIB2001.pdf. Accessed 9 September 2011

29. Health Systems Trust 2011 Medical scheme coverage. Available: http://www.healthlink.org.za/healthstats/77/data/eth. Accessed: 9 September 2011

30. South African National Cancer Registry 2011 Summary statistics of cancer diagnosed histologically in 2003 Johannesburg National Institute for Occupational Health Available: http://www.nioh.ac.za/assets/files/Cancer%20tables%202003.pdf. Accessed 8 September 2011

31. MishellDRJr 1997 Long-acting contraceptive steroids: postcoital contraceptives and antiprogestogens. LoboRAMishellDRJrPaulsonRJShoupeD Mishell's textbook of infertility, contraception and reproductive endocrinology, 4th edition Oxford Blackwell Science 827 850

32. GboladeBEllisSMurbyBRandallSKirkmanR 1998 Bone density in long term users of depot medroxyprogesterone acetate. Br J Obstet Gynaecol 105 790 794

33. Million Women Study Collaborators 2003 Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 419 427

34. Medicines and Healthcare Products Regulatory Agency 2007 UK public assessment report—hormone-replacement therapy: safety update London Medicines and Healthcare Products Regulatory Agency Available: http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con2032228.pdf. Accessed 1 January 2009

35. CanfellKBanksE 2010 Oral contraceptives and hormone replacement therapy, and cancers of the female reproductive system. RobotinMOlverIGirgisA When cancer crosses disciplines London Imperial College Press

36. International Agency for Research on Cancer 1979 Sex hormones Lyon International Agency for Research on Cancer